FDA rejects Sandoz's Neulasta copy, giving Amgen a break from the biosim onslaught

Tuesday, July 19, 2016

Amgen’s aging superstars have been under assault lately by Novartis’ Sandoz unit and its biosimilars ambitions. But the Big Biotech scored a break at the hands of regulators: The FDA rebuffed Sandoz's biosim version of Amgen's big-selling Neulasta, Novartis disclosed Tuesday.